thymosin beta-4 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-03. Anything still debated is marked as such rather than presented as settled.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
| Property | Value | Notes |
|---|---|---|
| Water content | Low in freshly lyophilised material | Rises after repeated opening of the same vial |
| Solution stability | Lower than powder stability | Frozen aliquots are preferred over repeated thawing |
| Purity assessment | Reversed-phase HPLC with UV detection | Peak-area percentage excludes salts and water |
| Salt form | Often the trifluoroacetate salt | Retained from acidic purification gradients |
| Light sensitivity | Not strongly photoreactive | Dark storage still advised for long-term keeping |
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
== Natural occurrences == Synephrine, although already known as a synthetic organic compound, was first isolated as a natural product from the leaves of various Citrus trees, and its presence noted in different Citrus juices, by Stewart and co-workers in the early 1960s. A survey of the distribution of synephrine amongst the higher plants was published in 1970 by Wheaton and Stewart. It has subsequently been detected in Evodia and Zanthoxylum species, all plants of the family Rutaceae. Trace levels (0.003%) of synephrine have also been detected in the dried leaves of Pogostemon cablin (patchouli, Lamiaceae). It is also found in certain cactus species of the genera Coryphantha and Dolichothele. However, this compound is found predominantly in a number of Citrus species, including "bitter" orange varieties.
Westbrook* (1968), writer, son of syndicated columnist Sheilah Graham Westbrook Phillip Lopate (1964), essayist and fiction writer Ron Padgett (1964), poet and translator, winner of the Shelley Memorial Award in 2009 and Robert Frost Medal in 2018 Steven Millhauser (1965), novelist and winner of the Pulitzer Prize for Fiction for Martin Dressler: The Tale of an American Dreamer Aaron Fogel (1967), poet Eric Van Lustbader (1967), espionage and thriller novelist, writer of Jason Bourne novels Thomas Hauser (1968), author of nonfiction and biographer David Shapiro (1968), poet, literary critic, professor at William Paterson University Hilton Obenzinger (1969), novelist, poet, history and criticism writer Paul Auster (1970), postmodern writer; author of The New York Trilogy, Moon Palace, and the Brooklyn Follies Bob Holman (1970), poet and activist identified with the oral tradition David Lehman (1970), poet, editor of The Best American Poetry series Joshua Rubenstein (1971), writer, winner of a National Jewish Book Award in 2002 Alex Abella (1972), Cuban-American writer Brad Gooch (1973), writer, professor of English at William Paterson University John Prados (1973), author and historian on World War II and the Cold War Todd McEwen (1975), writer, professor at the University of Kent Stephen O'Connor (1975), writer and professor at Sarah Lawrence College Damien Bona (1977), chronicler of the Academy Awards Mason Wiley (1977), co-author of The Official Preppy Handbook Kevin Baker (1980), novelist and freelance journalist Jeffrey Harrison (1980), poet who won the 1988 Amy Lowell Poetry Travelling Scholarship Lou Antonelli (1981), science fiction writer Douglas Sadownick (1981), writer and psychologist Michael Friedman (1982), novelist and author Michael Azerrad (1983), author, journalist, musician Thomas Dyja (1984), writer, historian, winner of the 1997 Casey Award David Rakoff (1986), comedic essayist Louise Wareham Leonard (1987), writer Al Weisel (1987), freelance writer Adrienne Brodeur (1988), author, program director at Aspen Institute Glen Hirshberg (1988), author, recipient of the 2007 Shirley Jackson Award Adam Mansbach (1988), author and former professor of literature at Rutgers University–Camden Darryl Pinckney (1988), novelist, playwright, and essayist Mako Yoshikawa (1988), novelist, professor at Emerson College Ben Coes (1989), author of political thriller and espionage novels Wade Graham (1989), author, historian, environmentalist G. Winston James (1989), poet, author, activist Robert Salkowitz (1989), author on technology innovation Carol Guess (1990), novelist and poet; professor at Western Washington University John Reed (1990), novelist; author of Snowball's Chance David S. Levinson (1991), short-story writer and novelist Robert Kolker (1991), writer, author of Hidden Valley Road Kelly Link (1991), Hugo Award-winning author; founder of Small Beer Press; editor of St. Martin's Press's Year's Best Fantasy and Horror Loren Goodman (1991), postmodern poet, professor at Underwood International College Andrew Carroll (1992), author, editor, activist, and historian Jordan Davis (1992), poet John Bemelmans Marciano (1992), children's book author and illustrator, grandson of Ludwig Bemelmans, author of Madeline Marie Mutsuki Mockett (1992), writer Melissa de la Cruz (1993), writer known for work in young adult fiction Jay Michaelson (1993), writer and LGBTQ activist Maxine Swann (1994), fiction writer Robert Westfield (1994), writer who won two Lambda Literary Awards Megan McCafferty (1995), chick lit writer, Jessica Darling series, which were plagiarized by Kaavya Viswanathan Tova Mirvis (1995), author Saleemah Abdul-Ghafur (1996), author and Islamic activist Fredrik Stanton (1996), author of Great Negotiations and former publisher for the Columbia Daily Spectator Aravind Adiga (1997), Man Booker Prize-winning novelist Jamel Brinkley (1997), author, winner of the 2018 Ernest J. Gaines Award for Literary Excellence John Coletti (1997), author Gotham Chopra (1997), author, son of health advocate Deepak Chopra Lauren Grodstein (1997), author, professor of Rutgers University–Camden Abdi Nazemian (1998), Iranian-American author, winner of the 2017 Lambda Literary Award for Debut Fiction Trevor Shane (1998), writer Daniel Alarcón (1999), novelist Katherine Howe (1999), novelist, author of The Physick Book of Deliverance Dane Rebecca Pawel (1999), author of mystery novels; winner of the 2004 Edgar Allan Poe Award for Best First Novel Alex Marzano-Lesnevich (2001), author, winner of a 2018 Lambda Literary Award and Chautauqua Prize Fiona Sze-Lorrain (2003), French writer, poet, translator, musician Ben Dolnick (2004), writer, son of biographer Edward Dolnick, member of the Ochs-Sulzberger family that owns The New York Times Danielle Valore Evans (2004), fiction writer Adam Gidwitz (2004), author of best selling children's books Alaya Dawn Johnson (2004), author and winner of the 2015 Andre Norton Award Tongo Eisen-Martin (2004), poet laureate of San Francisco Sidik Fofana (2005), public school teacher and writer, winner of a 2023 Whiting Award Victoria Loustalot (2006), writer of memoir and essays Crystal Hana Kim (2009), writer, If You Leave Me Morgan Parker (2010), poet and Cave Canem Fellow Rachel Heng (2011), Singaporean writer Ben Philippe (2011), author, screenwriter, recipient of the 2020 William C. Morris Award Rowan Hisayo Buchanan (2012), British-American writer, recipient of the Betty Trask Award and the Authors' Club Best First Novel Award Sylvia Khoury (2012), writer and playwright, recipient of a 2021 Whiting Award Yanyi (2013), poet
=== Laboratory Network === Gift of Hope Organ and Tissue Donor Network Laboratory (Itasca) HSHS St. Mary's Hospital Decatur, IL Illinois State University Loyola University Medical Center SHIELD Illinois Clinical Diagnostic Laboratory at UIC SHIELD Illinois COVID-19 Testing Lab (Springfield) SHIELD T3 Kentucky SHIELD T3 Madison SHIELD T3 UIC Simple Labs University of Illinois College of Medicine Rockford University of Illinois Urbana-Champaign Annex
=== Miscellaneous === Buprenorphine and dezocine are partial agonists of the MOR but antagonists of the KOR. Contrarily, eptazocine is an antagonist of the MOR but an agonist of the KOR; the same is also true for nalorphine and levallorphan. A variety of partial agonists or mixed agonists-antagonists of the MOR and KOR are also marketed, and include butorphanol, levorphanol, nalbuphine, pentazocine, and phenazocine. All of the aforementioned drugs may be described as opioid modulators instead of as pure antagonists. With the sole exception of nalorphine, all of the preceding are used as analgesics (by virtue of the fact that both MOR and KOR agonism independently confer pain relief). However, these opioid analgesics have atypical properties in comparison to the prototypical pure MOR full agonist opioid analgesics, such as less or no risk of respiratory depression for MOR partial agonists and antagonists, reduced or no euphoria, abuse potential, and dependence liability with MOR partial agonists/antagonists, and use- and dose-limiting side effects such as dysphoria and hallucinations with KOR agonists. In addition, by virtue of its KOR antagonism, buprenorphine (as buprenorphine/samidorphan (ALKS-5461) or buprenorphine/naltrexone to block its MOR agonism) is under investigation for the treatment of depression and cocaine dependence, as are other KOR antagonists such as aticaprant and, previously, JDTic and PF-4455242 (both discontinued due to toxicity concerns).
=== Neurotoxicity === Selegiline has been reported to protect against the damage caused by the potent dopaminergic and/or noradrenergic neurotoxins 6-hydroxydopamine (6-OHDA), N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4), and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in animals. Conversely, selegiline is ineffective in protecting against the serotonergic and noradrenergic neurotoxin 5,7-dihydroxytryptamine (5,7-DHT). Selegiline has also been reported to protect against methylenedioxymethamphetamine (MDMA)-induced serotonergic neurotoxicity in rodents. The serotonergic neurotoxicity of MDMA appears to be dependent on release of dopamine and its subsequent metabolism by MAO-B within serotonergic neurons into hydroxyl radicals, which is blocked by MAO-B inhibition. Likewise, selegiline prevented the serotonergic neurotoxicity of a combination of methylenedioxyaminoindane (MDAI) and dextroamphetamine. Conversely, selegiline failed to reduce the serotonergic neurotoxicity caused by fenfluramine and either did not affect or potentiated the serotonergic neurotoxicity caused by para-chloroamphetamine (PCA). In addition, findings are mixed and conflicting on whether selegiline prevents amphetamine- and methamphetamine-induced dopaminergic neurotoxicity in rodents. Although MAO-B-selective doses of selegiline protect against MDMA-induced serotonergic neurotoxicity in rodents, combination of amphetamines like MDMA with MAOIs, including selegiline, can produce serious complications, including serotonin syndrome, hypertensive crisis, and death.
Sources: en.wikipedia.org
27 March The Event Horizon Telescope team confirms that strong magnetic fields are spiralling at the edge of the Milky Way's central black hole, Sagittarius A*. A new image released by the team, similar to M87*, suggests that strong magnetic fields may be common to all black holes. A study calculates the production costs of diabetes medications such as insulin and ozempic and finds them to be much lower than market prices. 28 March – LHS 3844 b is confirmed as the first tidally locked super-Earth exoplanet. Promising innovations relating to global challenges are reported: researchers demonstrate simultaneous radiative cooling and solar power generation from the same area (13 Mar). Promising results of health and medical research are reported: a blood test against colon cancer (13 Mar), mice-tested antibody-mediated depletion of myeloid-biased hematopoietic stem cells against immune system aging (27 Mar). Hazard research is published: a small trial links micro- and nanoplastics in carotid artery plaque to higher cardio and mortality risks (6 Mar), U.S. land area of ~1200 km² is threatened by coastal subsidence by 2050 due to sea level rise (6 Mar), an EEA risk assessment finds Europe underprepared for climate risks across five broad clusters (11 Mar), a preprint trial suggests large language models could be used for tailored manipulation, being more persuasive than humans when using personal information (21 Mar).
Inorganic chemistry deals with synthesis and behavior of inorganic and organometallic compounds. This field covers chemical compounds that are not carbon-based, which are the subjects of organic chemistry. The distinction between the two disciplines is far from absolute, as there is much overlap in the subdiscipline of organometallic chemistry. It has applications in every aspect of the chemical industry, including catalysis, materials science, pigments, surfactants, coatings, medications, fuels, and agriculture.
There are damehoods for actress Imelda Staunton, fashion designer Anya Hindmarch and artist Tracey Emin, while former Prime Minister Gordon Brown is made a Companion of Honour. 15 June – Trooping the Colour, the King's birthday parade, takes place. 16 June – Euro 2024: In their first game of the tournament, England win 1–0 against Serbia. 17 June The actor Sir Ian McKellen is taken to hospital after falling off stage during a performance of Player Kings at London's Noël Coward Theatre. Data shows that the London Stock Exchange has become the most valuable in Europe for the first time since 2022. The BBC's Panorama documentary series shows recordings of instances of abuse at a school for children with special educational needs in Wallasey, Merseyside. 18 June – A review conducted into the first Stephen Lawrence murder investigation concludes that four retired detectives who worked on the case will not face any criminal charges over their actions during the investigation. 19 June Figures show inflation fell to the Bank of England's target of 2% in the year to May 2024, down from 2.3% the previous month, and the first time it has been at 2% since July 2021. A woman who accused a therapist of raping and sexually assaulting her at his clinic in London's Belsize Park in 2016 is awarded £200,000 in damages following a civil case she brought against him, after the Crown Prosecution Service did not pursue the case. Figures show that 880 migrants crossed the English Channel on 18 June, setting a new record for daily crossings.
Diagnostic criteria of MFS were agreed upon internationally in 1996. However, Marfan syndrome is often difficult to diagnose in children, as they typically do not show symptoms until reaching pubescence. A diagnosis is based on family history and a combination of major and minor indicators of the disorder, rare in the general population, that occur in one individual – for example: four skeletal signs with one or more signs in another body system such as ocular and cardiovascular in one individual. The following conditions may result from MFS, but may also occur in people without any known underlying disorder.
Organ on a chip applications: For example organoids can be used to model diseases with cells derived from patients or they can be used to investigate the development of different tissues (for example the nervous system) in humans and other animals. Some of these areas are further elaborated in the sections below:
Sources: en.wikipedia.org
== Activity == LepA exhibits uncoupled GTPase activity. This activity is stimulated by the ribosome to the same extent as the activity of EF-G, which is known to have the strongest ribosome-dependent GTPase activity among all characterized G proteins involved in translation. Conversely, uncoupled GTPase activity occurs when the ribosome stimulation of GTP cleavage is not directly dependent on protein synthesis. In the presence of GTP, LepA works catalytically. On the other hand, in the presence of the nonhydrolysable GTP – GDPNP – the LepA action becomes stoichiometric, saturating at about one molecule per 70S ribosomes. This data demonstrates that GTP cleavage is required for dissociation of LepA from the ribosome, which is demonstrative of a typical G protein. At low concentrations of LepA (less than or equal to 3 molecules per 70S ribosome), LepA specifically recognizes incorrectly translocated ribosomes, back-translocates them, and thus allows EF-G to have a second chance to catalyze the correct translocation reaction. At high concentrations (about 1 molecule per 70S ribosome), LepA loses its specificity and back-translocates every POST ribosome. This places the translational machinery in a nonreproductive mode. This explains the toxicity of LepA when it is found in a cell in high concentrations. Hence, at low concentrations LepA significantly improves the yield and activity of synthesized proteins; however, at high concentrations LepA is toxic to cells. Additionally, LepA has an effect on peptide bond formation.
Single display resolutions One 16K (15360 × 8640) display @ 60 Hz with 10 bpc (30 bit/px, HDR) RGB/Y′CBCR 4:4:4 color (with DSC) One 10K (10240 × 4320) display @ 60 Hz and 8 bpc (24 bit/px, SDR) RGB/Y′CBCR 4:4:4 color (uncompressed) Dual display resolutions Two 8K (7680 × 4320) displays @ 120 Hz and 10 bpc (30 bit/px, HDR) RGB/Y′CBCR 4:4:4 color (with DSC) Two 4K (3840 × 2160) displays @ 144 Hz and 8 bpc (24 bit/px, SDR) RGB/Y′CBCR 4:4:4 color (uncompressed) Triple display resolutions Three 10K (10240 × 4320) displays @ 60 Hz and 10 bpc (30 bit/px, HDR) RGB/Y′CBCR 4:4:4 color (with DSC) Three 4K (3840 × 2160) displays @ 90 Hz and 10 bpc (30 bit/px, HDR) RGB/Y′CBCR 4:4:4 color (uncompressed) When using only two lanes on the USB-C connector via DP Alt Mode to allow for simultaneous SuperSpeed USB data and video, DP 2.0 can enable such configurations as:
A subunit vaccine is a vaccine that contains purified parts of the pathogen that are antigenic, or necessary to elicit a protective immune response. Subunit vaccine can be made from dissembled viral particles in cell culture or recombinant DNA expression, in which case it is a recombinant subunit vaccine. A "subunit" vaccine doesn't contain the whole pathogen, unlike live attenuated or inactivated vaccine, but contains only the antigenic parts such as proteins, polysaccharides or peptides. Because the vaccine doesn't contain "live" components of the pathogen, there is no risk of introducing the disease, and is safer and more stable than vaccines containing whole pathogens. Other advantages include being well-established technology and being suitable for immunocompromised individuals. Disadvantages include being relatively complex to manufacture compared to some vaccines, possibly requiring adjuvants and booster shots, and requiring time to examine which antigenic combinations may work best. The first recombinant subunit vaccine was produced in the mid-1980s to protect people from Hepatitis B. Other recombinant subunit vaccines licensed include Engerix-B (hepatitis B), Gardasil 9 (Human Papillomavirus), Flublok (influenza), Shingrix (Herpes zoster) and Nuvaxovid (Coronavirus disease 2019). After injection, antigens trigger the production of antigen-specific antibodies, which are responsible for recognising and neutralising foreign substances. Basic components of recombinant subunit vaccines include recombinant subunits, adjuvants and carriers.
== Company history == BIA Separations was formed in 1998 by a group of scientists in Ljubljana, Slovenia to commercialize a new chromatographic resin based on monolith technology. Monolithic resin was developed independently by three different laboratories in late 1980s led by Hjertén, Švec and Tennikova. The company was one of the few Slovenian companies to receive venture capital funding at that time-Horizonte Venture Management realizing the potential of monoliths made the initial investment in the company. During that year, BIA Separations released its first commercial product marketed under the trade name of CIM (Convective Interaction Media). The new technique was named HPMC (High Performance Monolith Chromatography). During the 1999 and 2000s, the company promoted this new platform technology to the scientific and business community and registered several patents. In 2007 the company headquarters moved to Villach, Austria. In 2011 BIA Separations entered a strategic partnership with Japan Synthetic Rubber Corporation, a Japanese company producing synthetic materials. A strategic partnership agreement with Showa Denko K.K. (SDK) was signed in 2012.
Sources: en.wikipedia.org
Divide it into single-use aliquots and hold them frozen at -20 °C or below, protected from light. Repeated thawing of one container is the main avoidable source of variability.
Mass spectrometry confirms identity, because the measured mass is compared with the value expected from the sequence. Chromatography mainly reports how much of the material elutes as the target peak.
It usually describes the share of the chromatographic peak area recorded at a set wavelength. Salts, residual water, and solvent are excluded from that number, so it is not the same as mass fraction.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.